The new company will be a major player in seeds and pharmaceuticals, two cannabis sweet spots.
Here’s your daily round-up of pot-news, excerpted from the newsletter WeedWeek. Download WeedWeek’s free 2016 election guide here.
In one of the largest mergers ever, the German chemical and pharamaceutical giant Bayer will buy seed company Monsanto for $66 billion. Mainstream reports did not bring it up, but both companies have long been seen as interested in the plant. (Bayer has a partnership with GW Pharmaceuticals.) In July, the far-left site Counterpunch published a piece called “ Monsanto, Bayer and the Push for Corporate Cannabis.”
Cannabis Reports CEO David Drake publicly shamed Leafly and Weedmaps for poor cybersecurity. Social network MassRoots and data firm Headset announced a strategic partnership.
At an L.A. conference, Viridian Capital Advisors president Scott Greiper said legalization will bring about the next industrial revolution.
Canna Law Blog discusses what makes for a weak brand mark? New cannabis business lawyer Daniel Shortt explains why he’s chosen the specialty.
Business school student Cameron Lehman writes about opening a dispensary with his plastic surgeon mom. U.C. Berkeley’s Haas business school is starting a speaker and case study series on the green rush.
Medical testing company Quest Diagnostics says the number of Americans testing positive for illegal drugs reached a decade high of 4%. Among “safety-sensitive” workers it was 1.8 %, a slight increase.
A new study found that states with legal, accessible MED saw decreases in opioid use in adults 21-40.
Reason asks “ What will control freaks ban next?” The answer appears to be the southeast Asian plant Kratom, which the DEA is adding to the list of schedule I drugs. Wired calls Kratom a promising treatmentfor opiate addition.
Dana-Farber Cancer Institute blogged on whether MED benefits cancer patients.
Food Safety News picked up a Leafly story about how to know if weed is past its sell-by date.
